Dianthus Therapeutics Announces Positive Phase 2 Results for Claseprubart in Generalized Myasthenia Gravis; Data to Be Presented at 2025 AANEM Annual Meeting

Reuters

10/02

Dianthus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Phase 2 Results for Claseprubart in Generalized Myasthenia Gravis; Data to Be Presented at 2025 AANEM Annual Meeting

Dianthus Therapeutics Inc., a clinical-stage biotechnology company, announced that topline results from the Phase 2 MaGic trial of claseprubart (DNTH103), an active C1s inhibitor, in patients with generalized Myasthenia Gravis will be presented at the American Association of Neuromuscular and Electromagnetic Medicine (AANEM) Annual Meeting, scheduled for October 29 to November 1, 2025, in San Francisco, California. The company also plans to present additional analyses from the trial and new preclinical data regarding upstream inhibition. An oral presentation of the trial results will be delivered by Dr. Pushpa Narayanaswami, and a virtual industry forum featuring an expert panel will follow. The presentations are intended to highlight the potential benefits of claseprubart in the treatment of generalized Myasthenia Gravis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9538973-en) on October 02, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2572514951"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572514951\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572514951?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-02 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572514951","market":"fut","top_or_hot":-1,"title":"Dianthus Therapeutics Announces Positive Phase 2 Results for Claseprubart in Generalized Myasthenia Gravis; Data to Be Presented at 2025 AANEM Annual Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Dianthus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Phase 2 Results for Claseprubart in Generalized Myasthenia Gravis; Data to Be Presented at 2025 AANEM Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DNTH\">Dianthus Therapeutics Inc.</a>, a clinical-stage biotechnology company, announced that topline results from the Phase 2 MaGic trial of claseprubart (DNTH103), an active C1s inhibitor, in patients with generalized Myasthenia Gravis will be presented at the American Association of Neuromuscular and Electromagnetic Medicine (AANEM) Annual Meeting, scheduled for October 29 to November 1, 2025, in San Francisco, California. The company also plans to present additional analyses from the trial and new preclinical data regarding upstream inhibition. An oral presentation of the trial results will be delivered by Dr. Pushpa Narayanaswami, and a virtual industry forum featuring an expert panel will follow. The presentations are intended to highlight the potential benefits of claseprubart in the treatment of generalized Myasthenia Gravis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9538973-en) on October 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dianthus Therapeutics Announces Positive Phase 2 Results for Claseprubart in Generalized Myasthenia Gravis; Data to Be Presented at 2025 AANEM Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDianthus Therapeutics Announces Positive Phase 2 Results for Claseprubart in Generalized Myasthenia Gravis; Data to Be Presented at 2025 AANEM Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-02 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Dianthus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Phase 2 Results for Claseprubart in Generalized Myasthenia Gravis; Data to Be Presented at 2025 AANEM Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DNTH\">Dianthus Therapeutics Inc.</a>, a clinical-stage biotechnology company, announced that topline results from the Phase 2 MaGic trial of claseprubart (DNTH103), an active C1s inhibitor, in patients with generalized Myasthenia Gravis will be presented at the American Association of Neuromuscular and Electromagnetic Medicine (AANEM) Annual Meeting, scheduled for October 29 to November 1, 2025, in San Francisco, California. The company also plans to present additional analyses from the trial and new preclinical data regarding upstream inhibition. An oral presentation of the trial results will be delivered by Dr. Pushpa Narayanaswami, and a virtual industry forum featuring an expert panel will follow. The presentations are intended to highlight the potential benefits of claseprubart in the treatment of generalized Myasthenia Gravis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9538973-en) on October 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2095319765.USD","symbol_name":"Natixis Thematics Subscription Economy R/A USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nNDL6Dl5K5:1","article_id":"2572514951","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572514951","pubTimestamp":1759406425,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Dianthus Therapeutics Announces Positive Phase 2 Results for Claseprubart in Generalized Myasthenia Gravis; Data to Be Presented at 2025 AANEM Annual Meeting. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on October 02, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4585":"ETF&股票定投概念","DNTH":"Dianthus Therapeutics Inc.","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","NDAQ":"纳斯达克OMX交易所","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"Dianthus Therapeutics宣布Claseprubart治疗全身性重症肌无力的2期积极结果；将在2025年AANEM年会上公布的数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DNTH":0.9,"NDAQ":0.9},"content_text":"Dianthus Therapeutics Announces Positive Phase 2 Results for Claseprubart in Generalized Myasthenia Gravis; Data to Be Presented at 2025 AANEM Annual Meeting\n    \n\nDianthus Therapeutics Inc., a clinical-stage biotechnology company, announced that topline results from the Phase 2 MaGic trial of claseprubart (DNTH103), an active C1s inhibitor, in patients with generalized Myasthenia Gravis will be presented at the American Association of Neuromuscular and Electromagnetic Medicine (AANEM) Annual Meeting, scheduled for October 29 to November 1, 2025, in San Francisco, California. The company also plans to present additional analyses from the trial and new preclinical data regarding upstream inhibition. An oral presentation of the trial results will be delivered by Dr. Pushpa Narayanaswami, and a virtual industry forum featuring an expert panel will follow. The presentations are intended to highlight the potential benefits of claseprubart in the treatment of generalized Myasthenia Gravis.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9538973-en) on October 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}